NVS Novartis Aggregate Debt Obligations

Novartis AG (NVS) is advancing gene therapy and oncology through laboratory acquisitions and IT partnerships. High bioengineering costs and patent protection ensure the holding's revenue stability. Debt burden dynamics on GURU.Markets provide up-to-date data, where the indicator stands at 47.45, while the company simultaneously implements green chemistry principles and renewable energy in Europe.

Company Aggregate Debts: Novartis Inc. (NVS) for 07/04/2022 - 10/28/2026

Analytical breakdowns and data insights for company Novartis (NVS)

- price and consensus price forecast:

Stock Price Novartis Pharma|NVS - Price Target Chart

- market capitalization data:

Market Value Novartis Inc.|NVS - Total Company Value

- book capitalization data:

Accounting Value per Share Novartis|NVS - Book Capitalization|Market Capitalization to Book Value Ratio novartis.com|NVS - Cumulative Company Assets

- debt and liquidity data:

Fundamental company valuation:Novartis Pharma NVS

Signature product of Novartis Corporation

The integration of robotic reactors and AI into Novartis AG (NVS) laboratories requires significant capital expenditures. This indicator aggregates short-term and long-term banking obligations, quantifying the total cost of borrowed capital. Analyzing the total debt load allows for tracking the rate at which credit resources are deployed toward automation. An increase in this metric indicates expansion but heightens the stock's sensitivity to interest rates. Debt dynamics determine the stability of the issuer's financial leverage.

Competitors of Novartis AG